Sort   by:  
 Page size 
UnknownRandomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
Not available
S-EPMC4622102 | biostudies-literature
UnknownPhase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108.
Not available
S-EPMC4500834 | biostudies-literature
UnknownActive idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Not available
S-EPMC4039868 | biostudies-literature
UnknownBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Not available
S-EPMC4171358 | biostudies-literature
UnknownNivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022.
Not available
S-EPMC12277847 | biostudies-literature
UnknownCharacteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
Not available
S-EPMC8977231 | biostudies-literature
UnknownCharacteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
Not available
S-EPMC12306653 | biostudies-literature
UnknownMagrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial.
Not available
S-EPMC11609520 | biostudies-literature
UnknownPositron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
Not available
S-EPMC9928671 | biostudies-literature
UnknownBrentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.
Not available
S-EPMC12684812 | biostudies-literature
Sort   by:  
 Page size